PUBLISHER: Fairfield Market Research | PRODUCT CODE: 1397290
PUBLISHER: Fairfield Market Research | PRODUCT CODE: 1397290
The global Chemiluminescence Immunoassay market, which achieved a valuation of US$ 8.9 billion in 2024. By 2031, the market is expected to reach a valuation of US$ 21 billion, with the highest revenue generated through Chemiluminescence Immunoassay Consumables during the same period.
Chemiluminescence immunoassay solutions play a crucial role in diagnosing chronic health conditions such as autoimmune disorders, infectious diseases, diabetes, cardiovascular diseases, obesity, and cancer. They are also utilized in pharmaceutical manufacturing and research centers for therapeutic medication monitoring.
Recent advancements in diagnostic technology have led to significant progress in the identification of antibodies, making chemiluminescence immunoassay more automated and akin to clinical chemistry laboratories. The demand for these tests is expected to grow due to technical improvements in disease detection, increased need for preventive diagnosis, and treatment monitoring.
The proliferation of high-throughput laboratories is being witnessed as large-scale laboratories use aggressive scheduling technology to capitalize on their service and quality capabilities, outpacing small and medium-sized laboratories. Moreover, major medical laboratories worldwide are expanding their businesses through mergers and acquisitions, leading to an increase in laboratory tests and volume, which, in turn, drives the adoption of automation and integration, contributing to market growth.
Asia Pacific is expected to experience the fastest growth in the Chemiluminescence Immunoassay market during the forecast period. Growing awareness of chronic diseases in emerging economies like China and India, coupled with the approval and introduction of novel chemiluminescence immunoassay analyzer systems by local companies, is driving regional market expansion.
In North America, the market is expected to witness significant growth due to acquisitions made by key market players. Companies like PerkinElmer, Inc. are focusing on expanding their commercial diagnostics business through acquisitions and incorporating new chemiluminescence products in various areas of diagnostics.
The Chemiluminescence Immunoassay market is moderately competitive, with key players including DiaSorin S.p.A., Abbott Laboratories, Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Immunodiagnostic Systems, Siemens Healthineers, Beckman Coulter Inc., F. Hoffmann-La Roche AG, Inova Diagnostics, Inc., Maccura Biotechnology Co., Ltd., and Ortho Clinical Diagnostics.